Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Basilea Pharmaceutica AG
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Basilea Pharmaceutica AG
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Basilea Pharmaceutica AG
SIX:BSLN
Operating Expenses
-CHf122.5m
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
-5%
ADC Therapeutics SA
NYSE:ADCT
Operating Expenses
-$233m
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Operating Expenses
-CHf78.3m
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Operating Expenses
-$535.2m
CAGR 3-Years
-3%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Operating Expenses
-CHf85.9m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Operating Expenses
-CHf50.8m
CAGR 3-Years
-52%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
No Stocks Found

Basilea Pharmaceutica AG
Glance View

Market Cap
498.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
75.14 CHF
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Basilea Pharmaceutica AG's Operating Expenses?
Operating Expenses
-122.5m CHF

Based on the financial report for Jun 30, 2024, Basilea Pharmaceutica AG's Operating Expenses amounts to -122.5m CHF.

What is Basilea Pharmaceutica AG's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-5%

Over the last year, the Operating Expenses growth was -36%. The average annual Operating Expenses growth rates for Basilea Pharmaceutica AG have been 1% over the past three years , -1% over the past five years , and -5% over the past ten years .

Back to Top